STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review

Non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase ( ) rearrangement benefit from treatment with ALK inhibitors. Therefore, the identification of druggable fusions is necessary for NSCLC treatment. More than 90 fusion partners of have been reported in NSCLC patients, but the...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	OncoTargets and therapy 2020-01, Vol.13, p.12515-12519
Hauptverfasser:	Su, Cuiyun, Jiang, Ya, Jiang, Wei, Wang, Huilin, Liu, Sisi, Shao, Yang, Zhao, Wenhua, Ning, Ruiling, Yu, Qitao
Format:	Artikel
Sprache:	eng
Schlagworte:	Case Report
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!